Trial reportContemporary clinical trials2016
Non-invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA(3)CT): Design of a Phase IIb, placebo-controlled, double-blind, randomized clinical trial of doxycycline for the reduction of growth of small abdominal aortic aneurysm.
Trial report in Contemporary clinical trials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01756833 (Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial), which is not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA^3CT)
Who cites it
26 citing papers in PubMed, 53 citations in OpenAlex.
- Aortic calcification is associated with decreased abdominal aortic aneurysm growth.Scientific reports · 2025Trial
- A comparison of women and men with small abdominal aortic aneurysms.The British journal of surgery · 2025Trial
- Trial
- Review
- Precision Drug Delivery for Multifunctional Treatment of Abdominal Aortic Aneurysm Using Bioactive Tea Polyphenol Nanoparticles.ACS applied materials & interfaces · 2025Article
- Hyperglycemia inhibits AAA expansion: examining the role of lysyl oxidase.American journal of physiology. Heart and circulatory physiology · 2025Article
- Cross-sectional study of lung cancer patients as a potential high-risk factor for abdominal aortic aneurysm.PloS one · 2025Article
- Injectable Shear-Thinning Hydrogels with Sclerosing and Matrix Metalloproteinase Modulatory Properties for the Treatment of Vascular Malformations.Advanced functional materials · 2023Article
- Targeted PERK inhibition with biomimetic nanoclusters confers preventative and interventional benefits to elastase-induced abdominal aortic aneurysms.Bioactive materials · 2023Article
- Effect of Two Years of Doxycycline Treatment on Infrarenal Aortic Neck Diameter.EJVES vascular forum · 2023Article
- Genetic and Pharmacological Disruption of Interleukin-1α Leads to Augmented Murine Aortic Aneurysm.Annals of vascular surgery · 2022Article
- Development of pharmacotherapies for abdominal aortic aneurysms.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Peptide Amphiphile Supramolecular Nanofibers Designed to Target Abdominal Aortic Aneurysms.ACS nano · 2022Article
- The effect of diabetes on abdominal aortic aneurysm growth over 2 years.Journal of vascular surgery · 2022Article
- Role of volume in small abdominal aortic aneurysm surveillance.Journal of vascular surgery · 2022Article
- Targeting macrophage TFEB-14-3-3 epsilon Interface by naringenin inhibits abdominal aortic aneurysm.Cell discovery · 2022Article
- Cohort Study Examining the Association of Optimal Blood Pressure Control at Entry With Infrarenal Abdominal Aortic Aneurysm Growth.Frontiers in cardiovascular medicine · 2022Article
- Anatomic eligibility for endovascular aneurysm repair preserved over 2 years of surveillance.Journal of vascular surgery · 2021Article
- MMPs and ADAMs/ADAMTS inhibition therapy of abdominal aortic aneurysm.Life sciences · 2020Review
- Pathogenic mechanisms and the potential of drug therapies for aortic aneurysm.American journal of physiology. Heart and circulatory physiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
objectivesThe Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA(3)CT) is a Phase IIb randomized, placebo-controlled clinical trial, testing doxycycline (100mg bid) for inhibition of growth in the greatest transverse, orthogonal diameter of small abdominal aortic aneurysms (AAA).
methodsWe will enroll 258 patients, ≥55years of age who have AAA, men: 3.5-5.0cm and women: 3.5-4.5cm on CT scans confirmed centrally. The primary outcome is growth in maximal transverse, orthogonal diameter from baseline to 24-month follow-up. Secondary analyses address doxycycline effects on clinical events, aneurysm volume, and biomarkers. Primary analysis will be performed according to the principle of intention-to-treat accounting for death and ruptures by use of normal scores in analysis of covariance. At the time of the data file reported, 200 subjects have been randomized. We started enrollment in mid-2013 and will complete enrollment by mid-2016.
resultsParticipant average age=70.9years, (SD=7.6years) and maximum transverse diameter=4.3cm for men (SD=0.4) and 4.0cm for women (SD=0.3).
conclusionN-TA(3)CT is a critical experiment to determine whether doxycycline reduces growth of small AAA and systemic markers of inflammation previously seen in bench experiments and observational human studies to be associated with AAA growth. Our patient population baseline measurements agree with the design assumptions supporting our expectation of 90% power or greater to reject a null hypothesis in favor of an alternative hypothesis when growth is reduced by at least 40%. REGISTRATION: clinicaltrials.gov #NCT01756833.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.